A new study in the United States has found that women who take aspirin have a reduced risk of developing melanoma, and that the longer they take it, the lower the risk.
The findings suggest that aspirin’s anti-inflammatory effects may help protect against this type of skin cancer. The study was published early online on Monday in CANCER, a peer-reviewed journal of the American Cancer Society.
In the Women’s Health Initiative, researchers observed U.S. women aged 50 to 79 for an average of 12 years and noted which individuals developed cancer. At the beginning of the study, the women were asked which medications they took, what they ate, and what activities they performed.
When Jean Tang of Stanford University School of Medicine and her colleagues analyzed available data from 59,806 Caucasian women in the study, they found that women who took more aspirin were less likely to develop melanoma skin cancer during the 12 years of follow-up.
Overall, women who used aspirin had a 21-percent lower risk of melanoma relative to non-users. Each incremental increase in duration of aspirin use (less than one year of use, one to four years of use, and five or more years of use) was associated with an 11-percent lower risk of melanoma. Thus, women who used aspirin for five or more years had a 30-percent lower melanoma risk than women who did not use aspirin.
The researchers controlled for differences in pigmentation, tanning practices, sunscreen use, and other factors that may affect skin cancer risk.
“Aspirin works by reducing inflammation and this may be why using aspirin may lower your risk of developing melanoma,” said Tang. She noted that the findings support the design of a clinical trial to directly test whether aspirin can be taken to prevent melanoma.